During the past decade, Puskesmas Senen conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Puskesmas Senen" #1 collaborator was "Indonesia University" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Puskesmas Senen" are "Immunogenicity" (1 trials), "Safety Issues" (1 trials) and "Vaccine" (1 trials). Many other conditions were trialed in "Puskesmas Senen" in a lesser frequency.

Most popular intervention types in "Puskesmas Senen" are "Biological" (1 trials) and "Drug" (1 trials). Other intervention types were less common.

The name of intervention was led by "IPV Vaccine" (1 trials), "Vi Polysaccharide Vaccine" (1 trials), "Vi-DT Typhoid Conjugate Vaccine" (1 trials) and "Vi-DT Vaccine" (1 trials). Other intervention names were less common.

The vast majority of trials in "Puskesmas Senen" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Puskesmas Senen". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Puskesmas Senen, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Puskesmas Senen, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".